Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAGINE-3: Brodalumab vs Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis
2012-000667-24Phase 3Terminated
- Sponsor
- Amgen
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brodalumab in plaque psoriasis (3 arms), sponsored by Amgen. Primary endpoint: Co-primary efficacy endpoints: brodalumab vs placebo. Started May 2012; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2012-000667-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000667-24.